CFM
PYXS icon

Catalyst Funds Management’s Pyxis Oncology PYXS Stock Holding History

Catalyst Funds Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,400
Closed -$29.8K – 837
2026
Q1 		$29.8K Buy
+20,400
New +$30.7K 0.01% 563
2025
Q3 		– Sell
-23,200
Closed -$25.5K – 620
2025
Q2 		$25.5K Buy
+23,200
New +$26.1K 0.01% 413

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's PYXS Position: Q2 2026 in Review

Catalyst Funds Management sold out of Pyxis Oncology (PYXS) in Q2 2026, closing a stake of 20,400 shares — an estimated $29.8K sold.

Catalyst Funds Management first reported a position in PYXS in Q2 2025 and held it in 2 quarters. The position peaked at $29.8K in Q1 2026. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Catalyst Funds Management reported no remaining Pyxis Oncology position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 20,400 Pyxis Oncology shares in Q2 2026, an estimated $29.8K.
  • Catalyst Funds Management first reported a position in Pyxis Oncology in Q2 2025 and held it in 2 quarters.
  • Catalyst Funds Management's Pyxis Oncology position peaked at $29.8K in Q1 2026.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.